Bacterial DNA replication enzymes as targets for antibacterial drug discovery

Expert Opinion on Drug Discovery

Volumn 7, Issue 4, 2012, Pages 327-339

  Sanyal, Gautam ^a   Doig, Peter ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

antibacterial agents; antibiotics; bacterial DNA synthesis; bacterial targets; DNA gyrase; DNA helicase; DNA ligase; DNA polymerase; DNA primase; topoisomerase

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL ENZYME; DNA DIRECTED DNA POLYMERASE GAMMA; DNA PRIMASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GSK 299423; GYRASE INHIBITOR; HELICASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; UNCLASSIFIED DRUG;

CRYSTAL STRUCTURE; DNA REPLICATION; DRUG RESEARCH; ENZYME ANALYSIS; ENZYME STRUCTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REPLISOME; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIA; BINDING SITES; DNA GYRASE; DNA HELICASES; DNA LIGASES; DNA PRIMASE; DNA REPLICATION; DNA, BACTERIAL; DNA-DIRECTED DNA POLYMERASE; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NUCLEIC ACID SYNTHESIS INHIBITORS; PROTEIN INTERACTION DOMAINS AND MOTIFS; TOPOISOMERASE INHIBITORS;

EID: 84859364840     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.660478     Document Type: Review

References (117)

1. Noirot-Gros MF, Dervyn E, Wu LJ, et al. An expanded view of bacterial DNA replication. Proc Natl Acad Sci USA 2002;99:8342-7 (Pubitemid 34651054)
2. Yao NY, O'Donnell M. SnapShot: the replisome. Cell 2010;141:1088
3. Marians KJ. Understanding how the replisome works. Nat Struct Mol Biol 2008;15:125-7 (Pubitemid 351207523)
4. Kornberg A, Baker TA. DNA replication. 2nd edition. University Science Books; Sausalito, CA: 2005
5. Pomerantz RT, O'Donnell M. Replisome mechanics: insights into a twin DNA polymerase machine. Trends Microbiol 2007;15:156-64 A review of replisome function. (Pubitemid 46528254)
6. Syson K, Thirlway J, Hounslow AM, et al. Solution structure of the helicase-interaction domain of the primase DnaG: a model for helicase activation. Structure 2005;13:609-16
7. Mitscher LA. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem Rev 2005;105:559-92 (Pubitemid 40351634)
8. Maxwell A, Lawson DM. The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. Curr Top Med Chem 2003;3:283-303
9. Maxwell A. DNA gyrase as a drug target. Biochem Soc Trans 1999;27:48-53 (Pubitemid 29086006)
10. Maxwell A. DNA gyrase as a drug target. Trends Microbiol 1997;5:102-9 (Pubitemid 27139470)
11. Hoshino K, Sato K, Une T, et al. Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus. Antimicrob Agents Chemother 1989;33:1816-18 (Pubitemid 19239181)
12. Chu DT, Hallas R, Clement JJ, et al. Synthesis and antitumour activities of quinolone antineoplastic agents. Drugs Exp Clin Res 1992;18:275-82 (Pubitemid 23049656)
13. Roca J, Berger JM, Harrison SC, et al. DNA transport by a type II topoisomerase: direct evidence for a two-gate mechanism. Proc Natl Acad Sci USA 1996;93:4057-62 (Pubitemid 26144245)
14. Roca J, Wang JC. DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell 1994;77:609-16 Along with reference 15, proposes the two gate mechanism of DNA gyrase.
15. Roca J, Wang JC. The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. Cell 1992;71:833-40 Along with reference 14, proposes the two gate mechanism of DNA gyrase.
16. Bates AD, Maxwell A. The role of ATP in the reactions of type II DNA topoisomerases. Biochem Soc Trans 2010;38:438-42
17. Bates AD, Maxwell A. Energy coupling in type II topoisomerases: why do they hydrolyze ATP? Biochemistry (NY) 2007;46:7929-41 (Pubitemid 47053858)
18. Maxwell A, Costenaro L, Mitelheiser S, et al. Coupling ATP hydrolysis to DNA strand passage in type IIA DNA topoisomerases. Biochem Soc Trans 2005;33:1460-4 (Pubitemid 41779715)
19. Shen LL, Mitscher LA, Sharma PN, et al. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug - DNA binding model. Biochemistry (NY) 1989;28:3886-94 (Pubitemid 19125438)
20. Emami S, Shafiee A, Foroumadi A. Structural features of new quinolones and relationship to antibacterial activity against gram-positive bacteria. Mini Rev Med Chem 2006;6:375-86
21. Bush K, Pucci MJ. New antimicrobial agents on the horizon. Biochem Pharmacol 2011;82:1528-39 Recent review of the antibacterial drug discovery pipeline.
22. Collin F, Karkare S, Maxwell A. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol 2011;92:479-97 Recent review of DNA gyrase and selected inhibitors.
23. Takei M, Fukuda H, Kishii R, et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother 2001;45:3544-7 (Pubitemid 33107875)
24. Alt S, Mitchenall LA, Maxwell A, et al. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and E by aminocoumarin antibiotics. J Antimicrob Chemother 2011;66:2061-9
25. Anderle C, Stieger M, Burrell M, et al. Biological activities of novel gyrase inhibitors of the aminocoumarin class. Antimicrob Agents Chemother 2008;52:1982-90 (Pubitemid 351758533)
26. Oblak M, Kotnik M, Solmajer T. Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. Curr Med Chem 2007;14:2033-47 (Pubitemid 47578161)
27. Eakin AE, Green O, Hales N, et al. Pyrrolamide DNA gyrase inhibitors: Fragment-based NMR screening to antibacterial agents. Antimicrob Agents Chemother 2012; In press Describes the application of NMR and structure-based design in fragment-based lead generation.
28. Hull K, Green O, Singh A, et al. Novel DNA gyrase inhibitors: the effect of pyrrolamide variations at site 1 and site 2 upon potency [abstract F1-2027]. 48th Intersci. Conf. Antimicrob Agents Chemother; 2008
29. Sherer B, Basarab G, Hull K, et al. Novel DNA gyrase inhibitors: The effect of pyrrolamide linker variations upon potency [abstract F1-2026]. Abstr 48th Intersci. Conf. Antimicrob Agents Chemother; 2008
30. Tsai FT, Singh OM, Skarzynski T, et al. The high-resolution crystal structure of a 24-kDa gyrase B fragment from E. coli complexed with one of the most potent coumarin inhibitors, clorobiocin. Proteins 1997;28:41-52
31. Lesher GY, Froelich EJ, Gruett MD, et al. 1,8-naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Pharm Chem 1962;91:1063-5
32. Aubry A, Pan XS, Fisher LM, et al. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 2004;48:1281-8 (Pubitemid 38405482)
33. Kern G, Basarab GS, Andrews B, et al. A DNA gyrase inhibitor with a novel mode of inhibition and in vivo efficacy [abstract F1-1840]. 51st Intersci. Conf. Antimicrob. Agents Chemother; 2011
34. Chen CR, Malik M, Snyder M, et al. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J Mol Biol 1996;258:627-37 (Pubitemid 26145906)
35. Drlica K, Malik M, Kerns RJ, et al. Quinolone-mediated bacterial death. Antimicrob Agents Chemother 2008;52:385-92 Interesting paper on how quinolones kill bacteria. (Pubitemid 351170804)
36. Dwyer DJ, Kohanski MA, Hayete B, et al. Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli. Mol Syst Biol 2007;3:91
37. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol 2010;8:423-35
38. Krasin F, Hutchinson F. Repair of DNA double-strand breaks in Escherichia coli, which requires recA function and the presence of a duplicate genome. J Mol Biol 1977;116:81-98 (Pubitemid 8205769)
39. Yoshida H, Bogaki M, Nakamura M, et al. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother 1991;35:1647-50
40. Heddle J, Maxwell A. Quinolone-binding pocket of DNA gyrase: role of GyrB. Antimicrob Agents Chemother 2002;46:1805-15 (Pubitemid 34535201)
41. Critchlow SE, Maxwell A. DNA cleavage is not required for the binding of quinolone drugs to the DNA gyrase-DNA complex. Biochemistry (NY) 1996;35:7387-93
42. Marians KJ, Hiasa H. Mechanism of quinolone action. A drug-induced structural perturbation of the DNA precedes strand cleavage by topoisomerase IV. J Biol Chem 1997;272:9401-9 (Pubitemid 27154954)
43. Kampranis SC, Maxwell A. The DNA gyrase-quinolone complex. ATP hydrolysis and the mechanism of DNA cleavage. J Biol Chem 1998;273:22615-26 (Pubitemid 28399831)
44. Howard BM, Pinney RJ, Smith JT. Function of the SOS process in repair of DNA damage induced by modern 4-quinolones. J Pharm Pharmacol 1993;45:658-62 (Pubitemid 23226761)
45. Kohanski MA, Dwyer DJ, Hayete B, et al. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 2007;130:797-810 (Pubitemid 47332566)
46. Wang X, Zhao X, Malik M, et al. Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J Antimicrob Chemother 2010;65:520-4
47. Bax BD, Chan PF, Eggleston DS, et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 2010;466:935-40 Reports crystal structure of a DNA gyrase construct bound to novel quinolines.
48. Wohlkonig A, Chan PF, Fosberry AP, et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol 2010;17:1152-3
49. Laponogov I, Sohi MK, Veselkov DA, et al. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol 2009;16:667-9
50. Laponogov I, Pan XS, Veselkov DA, et al. Structural basis of gate-DNA breakage and resealing by type II topoisomerases. [Electronic Resource]. PLoS ONE 2010;5:e11338
51. Laponogov I, Veselkov DA, Sohi MK, et al. Breakage-reunion domain of streptococcus pneumoniae topoisomerase IV: crystal structure of a gram-positive quinolone target [Electronic Resource]. PLoS ONE 2007;2:e301
52. Bradbury BJ, Pucci MJ. Recent advances in bacterial topoisomerase inhibitors. Curr Opin Pharmacol 2008;8:574-81 Key review of bacterial topoisomerase type II inhibitors, especially quinolones.
53. Tse-Dinh YC. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases. Infect Disord Drug Targets 2007;7:3-9
54. Grossman TH, Bartels DJ, Mullin S, et al. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother 2007;51:657-66 (Pubitemid 46185287)
55. Mani N, Gross CH, Parsons JD, et al. In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class. Antimicrob Agents Chemother 2006;50:1228-37
56. Zhi C, Long ZY, Manikowski A, et al. Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors. J Med Chem 2006;49:1455-65 (Pubitemid 43271899)
57. Black MT, Stachyra T, Platel D, et al. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob Agents Chemother 2008;52:3339-49
58. Basarab GS, Beaudoin M-, Brassil P, et al. Gyrase inhibiting antibacterial agents: Structure-activity relationships for four isomeric tetrahydronaphthyridine spirocyclic pyrimidinetrionesimidinetriones [abstract F1-1839]. 51st Intersci. Conf. Antimicrob Agents Chemother; 2011
59. Miller AA, Bundy GL, Mott JE, et al. Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors. Antimicrob Agents Chemother 2008;52:2806-12
60. Reck F, Alm R, Brassil P, et al. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity. J Med Chem 2011;54:7834-47
61. Gomez L, Hack MD, Wu J, et al. Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis. Bioorg Med Chem Lett 2007;17:2723-7 (Pubitemid 46636267)
62. Wiener JJ, Gomez L, Venkatesan H, et al. Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains. Bioorg Med Chem Lett 2007;17:2718-22 (Pubitemid 46636268)
63. Miles TJ, Barfoot C, Brooks G, et al. Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases. Bioorg Med Chem Lett 2011;21:7483-8
64. Miles TJ, Axten JM, Barfoot C, et al. Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases. Bioorg Med Chem Lett 2011;21:7489-95
65. Geng B, Comita-Prevoir J, Eyermann CJ, et al. Exploring left-hand-side substitutions in the benzoxazinone series of 4-amino-piperidine bacterial type IIa topoisomerase inhibitors. Bioorg Med Chem Lett 2011;21:5432-5
66. Frick DN, Richardson CC. DNA primases. Annu Rev Biochem 2001;70:39-80 (Pubitemid 32662205)
67. Hegde VR, Pu H, Patel M, et al. Two new bacterial DNA primase inhibitors from the plant polygonum cuspidatum. Bioorg Med Chem Lett 2004;14:2275-7 (Pubitemid 38481405)
68. Chu M, Mierzwa R, Xu L, et al. Isolation and structure elucidation of sch 642305, a novel bacterial DNA primase inhibitor produced by penicillium verrucosum. J Nat Prod 2003;66:1527-30 (Pubitemid 38036699)
69. Wilson EM, Trauner D. Concise synthesis of the bacterial DNA primase inhibitor (+) -sch 642305. Org Lett 2007;9:1327-9
70. Garcia-Fortanet J, Carda M, Marco JA. Stereoselective synthesis of the bacterial DNA primase inhibitor sch 642305 and its C-4 epimer. Tetrahedron 2007;63:12131-7 (Pubitemid 47600291)
71. Agarwal A, Louise-May S, Thanassi JA, et al. Small molecule inhibitors of E. coli primase, a novel bacterial target. Bioorg Med Chem Lett 2007;17:2807-10 (Pubitemid 46636243)
72. Koepsell SA, Larson MA, Frey CA, et al. Staphylococcus aureus primase has higher initiation specificity, interacts with single-stranded DNA stronger, but is less stimulated by its helicase than Escherichia coli primase. Mol Microbiol 2008;68:1570-82 (Pubitemid 351725266)
73. Borowiec JA. DNA helicases. In: ML DePamphilis. editor. DNA Replication in Eukaryotic Cells. Cold Spring Harbor Laboratory Press; NY: 1996. p. 545-74
74. Schaeffer P, Headlam M, Dixon N. Protein-protein interactions in the bacterial replisome. Aust Biochem 2004;35:9-12
75. Wing RA, Bailey S, Steitz TA. Insights into the replisome from the structure of a ternary complex of the DNA polymerase III alpha-subunit. J Mol Biol 2008;382:859-69
76. Bailey S, Eliason WK, Steitz TA. Structure of hexameric DnaB helicase and its complex with a domain of DnaG primase. Science 2007;318:459-63 (Pubitemid 47614533)
77. Aiello D, Barnes MH, Biswas EE, et al. Discovery, characterization and comparison of inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicases. Bioorg Med Chem 2009;17:4466-76
78. Moir DT, Li B, Pai R, et al. Optimization of coumarin-based inhibitors of Staphylococcus aureus and Bacillus anthracis replicative DNA helicases [abstract. F1-1838]. 51st Intersci. Conf. Antimicrob Agents Chemother; 2011
79. Inoue R, Kaito C, Tanabe M, et al. Genetic identification of two distinct DNA polymerases, DnaE and PolC, that are essential for chromosomal DNA replication in Staphylococcus aureus. Molecular Genet Genomics 2001;266:564-71 (Pubitemid 33145118)
80. Tarantino PM Jr, Zhi C, Wright GE, et al. Inhibitors of DNA polymerase III as novel antimicrobial agents against gram-positive eubacteria. Antimicrob Agents Chemother 1999;43:1982-7 Original report of aniline uracil DNA polymerase inhibitors. (Pubitemid 29395196)
81. Daly JS, Giehl TJ, Brown NC, et al. In vitro antimicrobial activities of novel anilinouracils which selectively inhibit DNA polymerase III of gram-positive bacteria. Antimicrob Agents & Chemother 2000;44:2217-21 (Pubitemid 30484459)
82. Huang YP, Ito J. The hyperthermophilic bacterium thermotoga maritima has two different classes of family C DNA polymerases: evolutionary implications. Nucleic Acids Res 1998;26:5300-9 (Pubitemid 28542728)
83. Payne DJ, Gwynn MN, Holmes DJ, et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007;6:29-40 Interesting review on the challenges of antibiotic discovery. (Pubitemid 46020284)
84. Gwynn MN, Portnoy A, Rittenhouse SF, et al. Challenges of antibacterial discovery revisited. Ann N Y Acad Sci 2010;1213:5-19
85. Svenstrup N, Ehlert K, Ladel C, et al. New DNA polymerase IIIC inhibitors: 3-subtituted anilinouracils with potent antibacterial activity in vitro and in vivo. ChemMedChem 2008;3:1604-15
86. Srivastava SK, Dube D, Tewari N, et al. Mycobacterium tuberculosis NAD+- dependent DNA ligase is selectively inhibited by glycosylamines compared with human DNA ligase I. Nucleic Acids Res 2005;33:7090-101 (Pubitemid 43135685)
87. Nandakumar J, Nair PA, Shuman S. Last stop on the road to repair: structure of E. coli DNA ligase bound to nicked DNA-adenylate. Mol Cell 2007;26:257-71 (Pubitemid 46617333)
88. Odell M, Sriskanda V, Shuman S, et al. Crystal structure of eukaryotic DNA ligase-adenylate illuminates the mechanism of nick sensing and strand joining. Mol Cell 2000;6:1183-93
89. Wilkinson A, Day J, Bowater R. Bacterial DNA ligases. Mol Microbiol 2001;40:1241-8 (Pubitemid 32635295)
90. Shuman S. DNA ligases: progress and prospects. J Biol Chem 2009;284:17365-9 A good overview of DNA ligases.
91. Pascal JM. DNA and RNA ligases: structural variations and shared mechanisms. Curr Opin Struct Biol 2008;18:96-105
92. Barrow EW, Westbrook L, Bansal N, et al. Antimycobacterial activity of 2-methyl-adenosine. J Antimicrob Chemother 2003;52:801-8 (Pubitemid 37407808)
93. Lahiri SD, Gu R, Gao N, et al. Structure guided understanding of NAD+ recognition in bacterial DNA ligases. Chem Biol 2012; In press
94. Zhu H, Shuman S. Structure-guided mutational analysis of the nucleotidyltransferase domain of Escherichia coli NAD+-dependent DNA ligase (LigA). J Biol Chem 2005;280:12137-44
95. Han S, Chang JS, Griffor M. Structure of the adenylation domain of NAD(+)-dependent DNA ligase from Staphylococcus aureus. Acta Crystallograph Sect F Struct Biol Cryst Commun 2009;65:1078-82
96. Brotz-Oesterhelt H, Knezevic I, Bartel S, et al. Specific and potent inhibition of NAD+-dependent DNA ligase by pyridochromanones. J Biol Chem 2003;278:39435-42 (Pubitemid 37248499)
97. Pinko C, Chu S, Su Y, et al. Crystal structures of DNA ligase from pathogenic bacteria reveal extensive structural conservation and provide critical insight into protein-ligand interaction. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003
98. Gajiwala KS, Pinko C. Structural rearrangement accompanying NAD+ synthesis within a bacterial DNA ligase crystal. Structure 2004;12:1449-59 (Pubitemid 39092089)
99. Meier TI, Yan D, Peery RB, et al. Identification and characterization of an inhibitor specific to bacterial NAD+-dependent DNA ligases. FEBS J 2008;275:5258-71
100. Mills SD, Eakin AE, Buurman ET, et al. Novel bacterial NAD+-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo. Antimicrob Agents Chemother 2011;55:1088-96 Biochemical and structural analysis of a novel DNA ligase inhibitors, leading to efficacy in a murine infection model.
101. Stokes SS, Huynh H, Gowravaram M, et al. Discovery of bacterial NAD+-dependent DNA ligase inhibitors: optimization of antibacterial activity. Bioorg Med Chem Lett 2011;21:4556-60
102. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:235-42 (Pubitemid 30047768)
103. Ramachandran GN, Sasisekharan V. Conformation of polypeptides and proteins. Adv Protein Chem 1968;23:283-438
104. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function J Comput Chem. 1998;19:1639-62 (Pubitemid 128590223)
105. Sriskanda V, Shuman S. A second NAD(+)-dependent DNA ligase (LigB) in Escherichia coli. Nucleic Acids Res 2001;29:4930-4 (Pubitemid 34065406)
106. Charifson PS, Grillot AL, Grossman TH, et al. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem 2008;51:5243-63
107. Wang G, Klein MG, Tokonzaba E, et al. The structure of a DnaB-family replicative helicase and its interactions with primase. Nat Struct Mol Biol 2008;15:94-100
108. Albert JS, Blomberg N, Breeze AL, et al. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. Curr Top Med Chem 2007;7:1600-29 Good overview with examples of fragment-based lead generation. (Pubitemid 350131017)
109. Murray CW, Blundell TL. Structural biology in fragment-based drug design. Curr Opin Struct Biol 2010;20:497-507
110. Green O, Ni H, Singh A, et al. Novel DNA gyrase inhibitors: Structure-guided discovery and optimization of pyrrolamides [Abstract F-2025]. 48th Intersci. Con. Antimibrobial Agents Chemother; 2008
111. Wiles JA, Hashimoto A, Thanassi JA, et al. Isothiazolopyridones: synthesis, structure, and biological activity of a new class of antibacterial agents. J Med Chem 2006;49:39-42 (Pubitemid 43077320)
112. Wiles JA, Wang Q, Lucien E, et al. Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells. Bioorg Med Chem Lett 2006;16:1272-6 (Pubitemid 43143004)
113. Hutchings KM, Tran TP, Ellsworth EL, et al. Synthesis and antibacterial activity of the C-7 side chain of 3-aminoquinazolinediones. Bioorg Med Chem Lett 2008;18:5087-90
114. Tran TP, Ellsworth EL, Sanchez JP, et al. Structure-activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors. Bioorg Med Chem Lett 2007;17:1312-20 (Pubitemid 46240852)
115. Lubbers T, Angehrn P, Gmunder H, et al. Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors. Bioorg Med Chem Lett 2007;17:4708-14 (Pubitemid 47058923)
116. Angehrn P, Goetschi E, Gmuender H, et al. A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. synthesis and antibacterial properties. J Med Chem 2011;54:2207-24
117. Angehrn P, Buchmann S, Funk C, et al. New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine. J Med Chem 2004;47:1487-513 (Pubitemid 38327474)